CN111471639A - 一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 - Google Patents
一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 Download PDFInfo
- Publication number
- CN111471639A CN111471639A CN202010471551.1A CN202010471551A CN111471639A CN 111471639 A CN111471639 A CN 111471639A CN 202010471551 A CN202010471551 A CN 202010471551A CN 111471639 A CN111471639 A CN 111471639A
- Authority
- CN
- China
- Prior art keywords
- mmol
- sodium
- solution
- human
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000007788 liquid Substances 0.000 title claims description 20
- 239000000243 solution Substances 0.000 claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 27
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 24
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 24
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 claims abstract description 24
- 229960002773 hyaluronidase Drugs 0.000 claims abstract description 22
- 108010003272 Hyaluronate lyase Proteins 0.000 claims abstract description 19
- 239000012266 salt solution Substances 0.000 claims abstract description 19
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims abstract description 14
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 239000001540 sodium lactate Substances 0.000 claims abstract description 13
- 235000011088 sodium lactate Nutrition 0.000 claims abstract description 13
- 229940005581 sodium lactate Drugs 0.000 claims abstract description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 12
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940054269 sodium pyruvate Drugs 0.000 claims abstract description 12
- 239000007995 HEPES buffer Substances 0.000 claims abstract description 11
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 11
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 11
- 239000007993 MOPS buffer Substances 0.000 claims abstract description 11
- 239000003797 essential amino acid Substances 0.000 claims abstract description 11
- 235000020776 essential amino acid Nutrition 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 11
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 7
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000001110 calcium chloride Substances 0.000 claims abstract description 6
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 6
- 235000011148 calcium chloride Nutrition 0.000 claims abstract description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 6
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims abstract description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims abstract description 6
- 239000001103 potassium chloride Substances 0.000 claims abstract description 6
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 6
- 239000011780 sodium chloride Substances 0.000 claims abstract description 6
- 235000002639 sodium chloride Nutrition 0.000 claims abstract description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims abstract description 6
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 4
- 229940088710 antibiotic agent Drugs 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 4
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 102000009066 Hyaluronoglucosaminidase Human genes 0.000 claims description 21
- 210000002503 granulosa cell Anatomy 0.000 claims description 18
- 230000003204 osmotic effect Effects 0.000 claims description 13
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 12
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 8
- 229960001031 glucose Drugs 0.000 claims description 8
- 229960002743 glutamine Drugs 0.000 claims description 8
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002158 endotoxin Substances 0.000 claims description 5
- 239000011591 potassium Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229910001424 calcium ion Inorganic materials 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 229910001414 potassium ion Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 101000585728 Homo sapiens Protein O-GlcNAcase Proteins 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 210000002459 blastocyst Anatomy 0.000 claims description 3
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000005070 sampling Methods 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 229920003081 Povidone K 30 Polymers 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims 2
- 235000013923 monosodium glutamate Nutrition 0.000 claims 2
- 229940073490 sodium glutamate Drugs 0.000 claims 2
- 239000002585 base Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 210000004681 ovum Anatomy 0.000 abstract description 18
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract description 9
- 102000002322 Egg Proteins Human genes 0.000 abstract description 9
- 108010000912 Egg Proteins Proteins 0.000 abstract description 9
- 229920002674 hyaluronan Polymers 0.000 abstract description 9
- 229960003160 hyaluronic acid Drugs 0.000 abstract description 9
- 102000001974 Hyaluronidases Human genes 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 5
- 210000001771 cumulus cell Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 241000458966 Ennucula granulosa Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical compound NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0081—Purging biological preparations of unwanted cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Preparation (AREA)
Abstract
一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,用于处理卵子的颗粒细胞的透明质酸酶溶解于含有聚乙烯吡咯烷酮、抗菌素和人血白蛋白的盐溶液中配制而成;其中包含:氯化钠95.00~105.00mmol/L、氯化钾3.45~6.55mmol/L、硫酸镁0.55~0.65mmol/L、氯化钙1.75~2.22mmol/L、磷酸二氢钠0.18~0.39mmol/L、碳酸氢钠3.85~5.45mmol/L、HEPES和MOPS15.00~25.00mmol/L、葡萄糖0.38~0.68mmol/L、丙酮酸钠0.28~0.42mmol/L、乳酸钠12.48~23.68mmol/L、谷氨酰胺0.32mmol/L~0.84mmol/L、非必需氨基酸5~15mmol/L、人血白蛋白5~15mg/mL、硫酸庆大霉素7~14μg/mL、聚乙烯吡咯烷酮2~6g/L、透明质酸酶30~90IU/ml;制备方法为:称量好各种组分并溶于注射级用水中,并经0.2μm滤膜过滤灭菌后,取样测试;使pH值:7.00~7.40;渗透压:250~310mOsm/Kg;细菌内毒素:<0.25EU/ml;1细胞鼠胚培养到96h:≥80%的囊胚形成率。
Description
技术领域
本发明涉及辅助生殖卵丘细胞与卵子的分离技术,具体涉及一种用于人类辅助生殖的颗粒细胞去除液及其制备方法。
背景技术
透明质酸酶已广泛应用于辅助生殖技术中。其目的是分离卵子周围的卵丘细胞(即颗粒细胞)。透明质酸酶的预期用途:用于卵子显微注射和卵子冷冻之前的卵丘细胞与卵子的分离。
卵子胞浆单精子注射(ICSI)或者卵子冷冻技术中,卵子必须与其周围的卵丘细胞(即颗粒细胞)中分离以便观察卵子的成熟和质量。颗粒细胞分散在粘稠的透明质酸中,透明质酸是一种粘多糖,而“消化”这道屏障的武器就是透明质酸酶。透明质酸酶(hyaluronidase)是能使透明质酸产生低分子化作用酶的总称,一种能够降低体内透明质酸的活性,从而提高组织中液体渗透能力的酶。透明质酸酶可以有效地消化颗粒细胞间的透明质酸,以便通过剥卵吸管(针)机械地去除卵子周围的颗粒细胞,随后实施单精子注射或者卵子冷冻技术。
聚乙烯吡咯烷酮(polyvinyl pyrrolidone)简称PVP,是一种非离子型高分子化合物,是N-乙烯基酰胺类聚合物中最具特色的,且被研究得最深、广泛的精细化学品品种。PVP有优良的生理惰性,不参与人体新陈代谢,又具有优良的生物相容性,对皮肤、粘膜、眼等不形成任何刺激。医药级PVP为国际倡导的三大药用新辅料之一,可用做片剂、颗粒剂的粘结剂、注射剂的助溶剂、胶囊的助流剂;眼药的去毒剂,延效剂,润滑剂和包衣成膜剂,液体制剂的分散剂和酶及热敏药物的稳定剂,还可用做低温保存剂。
辅助生殖技术中的颗粒细胞去除液中发挥作用的成份为透明质酸酶。而我国的颗粒细胞去除液几乎完全依赖进口成品,不仅成本高,且溶液经长途运输和海关检查后,其有效性受到不同程度的影响,甚至变质,如果使用低质或变质的溶液,将对辅助生殖的治疗带来不可逆转的后果和风险。
发明内容
本发明的目的是针对现有技术中的不足,提供一种更优良的用于人类辅助生殖的颗粒细胞去除液。
本发明的另一的目的是,提供一种用于人类辅助生殖的颗粒细胞去除液的制备方法。
为解决上述问题,本发明所采用的技术方案是:
一种用于人类辅助生殖的颗粒细胞去除液,用于处理卵子的颗粒细胞的透明质酸酶溶解于含有聚乙烯吡咯烷酮(Polyvinyl Pyrrolidone,PVP)、抗菌素和人血白蛋白的盐溶液中配制而成。
优选的,所述透明质酸酶为透明质酸酶(羊睾丸),浓度为30~90IU/ml。
优选的,所述聚乙烯吡咯烷酮为PVP-K30,浓度为2~6g/L。
优选的,所述抗菌素为硫酸庆大霉素,浓度为7~14μg/ml。
优选的,所述人血白蛋白浓度为5~15mg/mL。
优选的,所述盐溶液是以4-(2-羟乙基)-1-哌嗪乙磺酸(HEPES)和3-(N-吗啉基)丙磺酸(MOPS)为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、谷氨酰胺、非必需氨基酸为能量物质的化合物培养溶液;其中包含:氯化钠95.00~105.00mmol/L、氯化钾3.45~6.55mmol/L、硫酸镁0.55~0.65mmol/L、氯化钙1.75~2.22mmol/L、磷酸二氢钠0.18~0.39mmol/L、碳酸氢钠3.85~5.45mmol/L、HEPES和MOPS 15.00~25.00mmol/L、葡萄糖0.38~0.68mmol/L、丙酮酸钠0.28~0.42mmol/L、乳酸钠12.48~23.68mmol/L、谷氨酰胺0.32mmol/L~0.84mmol/L、非必需氨基酸5~15mmol/L。
为实现上述第二个目的,本发明采取的技术方案是:
一种用于人类辅助生殖的颗粒细胞去除液的制备方法,包括以下步骤:
(1)称量各种无机盐组分溶于注射级用水中,配制成盐溶液,
(2)加入硫酸庆大霉素、葡萄糖、丙酮酸钠、乳酸钠和谷氨酰胺溶于盐溶液中;溶解过程先加固体原料,再加液体原料;
(3)加入所述非必需氨基酸,聚乙烯吡咯烷酮(PVP),人血白蛋白以及透明质酸酶;
(4)检测步骤(3)所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250~310mOsm/Kg,所述pH值保持为7.00~7.40;
(5)将步骤(4)所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、pH值:7.00~7.40;
B、渗透压:250~310mOsm/Kg;
C、内毒素:<0.25EU/ml;
D、1细胞鼠胚培养到96h:≥80%的囊胚形成率;
(6)将配置好的溶液进行无菌分装和贴标签。
附图说明
图1为实施例1用于去除小鼠卵子周围的颗粒细胞的使用效果对比1;
图2为实施例2用于去除小鼠卵子周围的颗粒细胞的使用效果对比2。
图中:1、卵子;2、颗粒细胞。
具体实施方式
下面将对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式仅仅是本发明的一部分实施方式,而不是全部的实施方式。
文中所述的硫酸庆大霉素、人血白蛋白均为符合药典要求的药品;4-(2-羟乙基)-1-哌嗪乙磺酸(HEPES)、3-(N-吗啉基)丙磺酸(MOPS)、氯化钠、氯化钾、硫酸镁、氯化钙、磷酸二氢钠、碳酸氢钠、葡萄糖、丙酮酸钠、乳酸钠、谷氨酰胺、非必需氨基酸等均为低细菌内毒素(细菌内毒素<0.25EU/ml)的化学试剂。非必需氨基酸为L-丙氨酸、L-天冬酰胺、L-天冬氨酸、L-谷氨酸、甘氨酸、L-脯氨酸、L-丝氨酸等比例的混合物。
实施例1一种用于人类辅助生殖的颗粒细胞去除液
所述盐溶液是以HEPES和MOPS为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、谷氨酰胺、非必需氨基酸为能量物质的化合物培养溶液;其中包含:氯化钠95.45mmol/L、氯化钾3.85mmol/L、硫酸镁0.65mmol/L、氯化钙2.12mmol/L、磷酸二氢钠0.28mmol/L、碳酸氢钠5.25mmol/L、HEPES和MOPS 25.00mmol/L、葡萄糖0.46mmol/L、丙酮酸钠0.32mmol/L、乳酸钠14.45mmol/L、谷氨酰胺0.41mmol/L、人血白蛋白12mg/mL、非必须氨基酸5mmol/L、硫酸庆大霉素12μg/mL、聚乙烯吡咯烷酮6g/L、透明质酸酶80IU/ml。
具体制备方法包括以下步骤:
(1)称量各种无机盐组分溶于注射级用水中,配制成盐溶液,
(2)加入硫酸庆大霉素、葡萄糖、丙酮酸钠、乳酸钠和谷氨酰胺溶于盐溶液中;溶解过程先加固体原料,再加液体原料;
(3)加入所述非必需氨基酸,聚乙烯吡咯烷酮(PVP),人血白蛋白以及透明质酸酶;
(4)检测步骤(3)所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250~310mOsm/Kg,所述pH值保持为7.00~7.40;
(5)将步骤(4)所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、pH值:7.00~7.40;
B、渗透压:250~310mOsm/Kg;
C、内毒素:<0.25EU/ml;
D、1细胞鼠胚培养到96h:≥80%的囊胚形成率;
(6)将配置好的溶液进行无菌分装和贴标签。
实施例2一种用于人类辅助生殖的颗粒细胞去除液
所述盐溶液是以HEPES和MOPS为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、谷氨酰胺、非必需氨基酸为能量物质的化合物培养溶液;其中包含:氯化钠97.55mmol/L、氯化钾3.55mmol/L、硫酸镁0.55mmol/L、氯化钙1.88mmol/L、磷酸二氢钠0.22mmol/L、碳酸氢钠4.15mmol/L、HEPES和MOPS 22.5mmol/L、葡萄糖0.54mmol/L、丙酮酸钠0.38mmol/L、乳酸钠22.45mmol/L、谷氨酰胺0.82mmol/L,人血白蛋白14mg/mL、非必须氨基酸10mmol/L、硫酸庆大霉素14μg/mL、聚乙烯吡咯烷酮3g/L、透明质酸酶50IU/ml。
一种用于人类辅助生殖的颗粒细胞去除液的使用方法
在实验室里,将颗粒细胞去除液在37℃的培养箱内预热至少30分钟,然后,将卵子置于含有颗粒细胞去除液的培养皿内;在37℃的环境下孵育60秒,通过显微镜观察,用剥卵吸管(针)机械的去除卵子周围的颗粒细胞,然后洗涤剥除颗粒细胞的卵子,并移到37℃的CO2培养箱内培养,为单精子注射或者卵子冷冻保存备用。
本发明颗粒细胞去除液与现有的颗粒细胞去除液不同,其添加聚乙烯吡咯烷酮。作为一种合成水溶性高分子化合物,在颗粒细胞去除液中添加2-6g/L浓度的聚乙烯吡咯烷酮,使颗粒细胞去除液中的透明质酸酶顺利与其水溶液中的聚乙烯吡咯烷酮形成络合反应,可保证在使用过程中长效稳定的释放透明质酸酶发生作用。再者聚乙烯吡咯烷酮是一种非离子型高分子化合物,其分子长链可形成胶体保护作用,可持久的保护透明质酸酶不被颗粒细胞去除液中的其他物质降解。其添加的硫酸庆大霉素对革兰阴性和阳性细菌及支原体有抑菌或杀菌作用,比现有配方中的青霉素更能有效地抑制和杀死细菌。且庆大霉素是为数不多的热稳定性的抗生素,而青霉素的钾盐和钠盐的水溶液均很不稳定。其添加的HEPES和MOPS缓冲系统可以避免颗粒细胞去除液对CO2的依赖性,这一缓冲系统在空气中可以维持生理pH。且具有使细胞膜稳定、不与金属离子结合等优点。颗粒细胞去除液中添加蛋白的作用包括通过结合脂肪酸抑制脂肪的过氧化反应,从而稳定和保护细胞膜;结合各种抗体,重金属、脂蛋白和未明确的毒性物质;维持交替渗透压的稳定。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (7)
1.一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,用于处理卵子的颗粒细胞的透明质酸酶溶解于含有聚乙烯吡咯烷酮(Polyvinyl Pyrrolidone,PVP)、抗菌素和人血白蛋白的盐溶液中配制而成。
2.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述透明质酸酶为透明质酸酶(羊睾丸),浓度为30~90IU/ml。
3.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述聚乙烯吡咯烷酮为PVP-K30,浓度为2~6g/L。
4.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述抗菌素为硫酸庆大霉素,浓度为7~14μg/ml。
5.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述人血白蛋白浓度为5~15mg/mL。
6.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述盐溶液是以4-(2-羟乙基)-1-哌嗪乙磺酸(HEPES)和3-(N-吗啉基)丙磺酸(MOPS)为缓冲剂,以钠、钾、镁、钙离子为基础,并以葡萄糖、丙酮酸钠、乳酸钠、谷氨酰胺、非必需氨基酸为能量物质的化合物培养溶液;其中包含:氯化钠95.00~105.00mmol/L、氯化钾3.45~6.55mmol/L、硫酸镁0.55~0.65mmol/L、氯化钙1.75~2.22mmol/L、磷酸二氢钠0.18~0.39mmol/L、碳酸氢钠3.85~5.45mmol/L、HEPES和MOPS 15.00~25.00mmol/L、葡萄糖0.38~0.68mmol/L、丙酮酸钠0.28~0.42mmol/L、乳酸钠12.48~23.68mmol/L、谷氨酰胺0.32mmol/L~0.84mmol/L、非必需氨基酸5~15mmol/L。
7.根据权利要求1所述的一种用于人类辅助生殖的颗粒细胞去除液及其制备方法,其特征在于,所述制备方法包括以下步骤:
(1)称量各种无机盐组分溶于注射级用水中,配制成盐溶液,
(2)加入硫酸庆大霉素、葡萄糖、丙酮酸钠、乳酸钠和谷氨酰胺溶于盐溶液中;溶解过程先加固体原料,再加液体原料;
(3)加入所述非必需氨基酸,聚乙烯吡咯烷酮(PVP),人血白蛋白以及透明质酸酶;
(4)检测步骤(3)所得盐溶液的渗透压和pH值,并记录最终渗透压和pH值;所述渗透压保持为250~310mOsm/Kg,所述pH值保持为7.00~7.40;
(5)将步骤(4)所得溶液经过0.2μm滤膜过滤灭菌后,取样测试;测试参数:
A、pH值:7.00~7.40;
B、渗透压:250~310mOsm/Kg;
C、内毒素:<0.25EU/ml;
D、1细胞鼠胚培养到96h:≥80%的囊胚形成率;
(6)将配置好的溶液进行无菌分装和贴标签。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010471551.1A CN111471639A (zh) | 2020-05-29 | 2020-05-29 | 一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010471551.1A CN111471639A (zh) | 2020-05-29 | 2020-05-29 | 一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111471639A true CN111471639A (zh) | 2020-07-31 |
Family
ID=71763528
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010471551.1A Pending CN111471639A (zh) | 2020-05-29 | 2020-05-29 | 一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111471639A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114075542A (zh) * | 2021-11-02 | 2022-02-22 | 上海交通大学医学院附属第九人民医院 | 一种胞浆机械脱离用培养液及其使用方法 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688200A (zh) * | 2012-05-09 | 2012-09-26 | 刘锋 | 植物类抗癌靶向纳米制剂及其制备方法 |
CN104140952A (zh) * | 2014-08-08 | 2014-11-12 | 山东威高新生医疗器械有限公司 | 透明质酸酶及其制备方法 |
CN106031721A (zh) * | 2015-03-11 | 2016-10-19 | 上海瑞亦康生物科技有限公司 | 含有虾红素的提取物的组成物及其用途 |
CN106916800A (zh) * | 2017-02-15 | 2017-07-04 | 瑞柏生物(中国)股份有限公司 | 一种重组人颗粒细胞酶溶液及其制备方法 |
CN107099553A (zh) * | 2017-06-19 | 2017-08-29 | 内蒙古大学 | 一种小鼠体细胞核移植方法 |
CN108368483A (zh) * | 2015-09-17 | 2018-08-03 | 学校法人东京农业大学 | 将原始生殖细胞分化为功能上成熟的卵母细胞的培养方法 |
CN108473484A (zh) * | 2015-10-01 | 2018-08-31 | 赛诺米克斯公司 | 可用作trpm8调节剂的化合物 |
CN110643569A (zh) * | 2019-11-29 | 2020-01-03 | 广州达瑞生殖技术有限公司 | 一种颗粒细胞剥离液及其制备方法 |
-
2020
- 2020-05-29 CN CN202010471551.1A patent/CN111471639A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102688200A (zh) * | 2012-05-09 | 2012-09-26 | 刘锋 | 植物类抗癌靶向纳米制剂及其制备方法 |
CN104140952A (zh) * | 2014-08-08 | 2014-11-12 | 山东威高新生医疗器械有限公司 | 透明质酸酶及其制备方法 |
CN106031721A (zh) * | 2015-03-11 | 2016-10-19 | 上海瑞亦康生物科技有限公司 | 含有虾红素的提取物的组成物及其用途 |
CN108368483A (zh) * | 2015-09-17 | 2018-08-03 | 学校法人东京农业大学 | 将原始生殖细胞分化为功能上成熟的卵母细胞的培养方法 |
CN108473484A (zh) * | 2015-10-01 | 2018-08-31 | 赛诺米克斯公司 | 可用作trpm8调节剂的化合物 |
CN106916800A (zh) * | 2017-02-15 | 2017-07-04 | 瑞柏生物(中国)股份有限公司 | 一种重组人颗粒细胞酶溶液及其制备方法 |
CN107099553A (zh) * | 2017-06-19 | 2017-08-29 | 内蒙古大学 | 一种小鼠体细胞核移植方法 |
CN110643569A (zh) * | 2019-11-29 | 2020-01-03 | 广州达瑞生殖技术有限公司 | 一种颗粒细胞剥离液及其制备方法 |
Non-Patent Citations (3)
Title |
---|
刘锋;杨华;卢克焕;丘映;: "卵丘细胞线粒体移植对年老小鼠早期胚胎发育的影响" * |
李培旭,李尚为,彭芝兰,李蕾,马黔红,黄仲英,唐宗蓉,韩字研: "激光辅助法精子制动在睾丸精子卵母细胞内单精子注射中的应用" * |
毛晶;李钟淑;蔡文莲;胡艳明;祖晶;王士勇;方南洙;: "聚乙烯醇、聚乙烯吡咯烷酮和牛血清白蛋白对牛卵母细胞成熟及体细胞克隆胚胎发育的影响" * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114075542A (zh) * | 2021-11-02 | 2022-02-22 | 上海交通大学医学院附属第九人民医院 | 一种胞浆机械脱离用培养液及其使用方法 |
CN114075542B (zh) * | 2021-11-02 | 2024-02-20 | 上海交通大学医学院附属第九人民医院 | 一种胞浆机械脱离用培养液及其使用方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6843824B2 (ja) | 細胞培地および方法 | |
KR102193132B1 (ko) | 트레할로스 및 덱스트란 함유 포유동물 세포 이식용 용액 | |
AU2017377309B2 (en) | Mammalian cell cryopreservation liquid | |
KR101160198B1 (ko) | 췌장 소도의 분리방법 | |
US20190274300A1 (en) | Preservative solution for live cells or composition containing live cells | |
WO2019131940A1 (ja) | 多能性幹細胞凝集抑制剤 | |
CN111471639A (zh) | 一种用于人类辅助生殖的颗粒细胞去除液及其制备方法 | |
Blake et al. | Protein supplementation of human IVF culture media | |
US20190275088A1 (en) | Preservative solution for live cells or composition containing live cells | |
CN116458493A (zh) | 一种无dmso的干细胞保存液及其制备方法和使用方法 | |
CN110643569B (zh) | 一种颗粒细胞剥离液及其制备方法 | |
CN106916800A (zh) | 一种重组人颗粒细胞酶溶液及其制备方法 | |
EP3454652B1 (en) | Solution for the preservation, transport and application of stem cells | |
CN110452868A (zh) | 一种一步式胚胎培养液 | |
CN116218831A (zh) | 乙醇氧化酶稳定化纳米粒子及制备方法、应用和解酒药 | |
CN113999810B (zh) | 一种mrc-5细胞复苏培养液以及复苏方法 | |
RU2745114C1 (ru) | Средство для органотипической консервации донорской роговицы | |
CN113383768B (zh) | 一种肝细胞冻存液及其制备方法和应用 | |
US20240285693A1 (en) | Expansion of retinal pigment epithelium cells | |
JP5650480B2 (ja) | 細胞シートの製造方法 | |
US20180355304A1 (en) | Chemically defined media for the growth or detection of microorganisms | |
RU2290433C2 (ru) | Среда для консервации клеток островков лангерганса | |
CN118546863A (zh) | 一种人卵子或胚胎的玻璃化解冻液及其制备方法 | |
WO2008096196A1 (en) | A medium for cell culture | |
FR2949118A1 (fr) | Milieu de conservation d'organes, de tissus biologiques ou de cellules vivantes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200731 |